中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2015年
26期
5-6,7
,共3页
刘颖%张勤勇%何兴坤%刘瑜
劉穎%張勤勇%何興坤%劉瑜
류영%장근용%하흥곤%류유
头孢他美酯%慢严舒柠咽炎片%咽喉炎
頭孢他美酯%慢嚴舒檸嚥炎片%嚥喉炎
두포타미지%만엄서저인염편%인후염
Cefetamet pivoxil%Manyanshuning Yanyan tablets%Pharyngolaryngitis
目的:观察口服盐酸头孢他美酯辅以慢严舒柠咽炎片治疗急性和慢性咽喉炎的临床疗效和安全性。方法258例急慢性咽喉炎患者,随机分为试验组140例(其中急性咽喉炎76例为试验组1,慢性咽喉炎64例为试验组2)和对照组118例(其中急性咽喉炎60例为对照组1,慢性咽喉炎58例为对照组2)。急性咽喉炎,试验组给予盐酸头孢他美酯片+慢严舒柠咽炎片治疗,对照组给予氨苄青霉素+慢严舒柠咽炎片治疗,疗程为5~10 d;慢性咽喉炎给予相同治疗,疗程为5~21 d。对比两组疗效及盐酸头孢他美酯片+慢严舒柠咽炎片治疗急性和慢性咽喉炎的疗效和安全性。结果急性咽炎有效率试验组1为97.37%,对照组1为88.33%,差异有统计学意义(P<0.05);慢性咽喉炎有效率试验组2为90.63%,对照组2为84.48%,差异无统计学意义(P>0.05);试验组治疗急性咽喉炎与慢性咽喉炎的疗效差异无统计学意义(P>0.05),但急性咽喉炎的疗效好于慢性咽喉炎;试验组发生轻度不良反应2例,对照组1例,差异无统计学意义(P>0.05)。结论盐酸头孢他美酯辅以慢严舒柠咽炎片治疗急慢性咽喉炎疗效显著,且不良反应小,急性咽喉炎的疗效好于慢性咽喉炎,值得临床推广。
目的:觀察口服鹽痠頭孢他美酯輔以慢嚴舒檸嚥炎片治療急性和慢性嚥喉炎的臨床療效和安全性。方法258例急慢性嚥喉炎患者,隨機分為試驗組140例(其中急性嚥喉炎76例為試驗組1,慢性嚥喉炎64例為試驗組2)和對照組118例(其中急性嚥喉炎60例為對照組1,慢性嚥喉炎58例為對照組2)。急性嚥喉炎,試驗組給予鹽痠頭孢他美酯片+慢嚴舒檸嚥炎片治療,對照組給予氨芐青黴素+慢嚴舒檸嚥炎片治療,療程為5~10 d;慢性嚥喉炎給予相同治療,療程為5~21 d。對比兩組療效及鹽痠頭孢他美酯片+慢嚴舒檸嚥炎片治療急性和慢性嚥喉炎的療效和安全性。結果急性嚥炎有效率試驗組1為97.37%,對照組1為88.33%,差異有統計學意義(P<0.05);慢性嚥喉炎有效率試驗組2為90.63%,對照組2為84.48%,差異無統計學意義(P>0.05);試驗組治療急性嚥喉炎與慢性嚥喉炎的療效差異無統計學意義(P>0.05),但急性嚥喉炎的療效好于慢性嚥喉炎;試驗組髮生輕度不良反應2例,對照組1例,差異無統計學意義(P>0.05)。結論鹽痠頭孢他美酯輔以慢嚴舒檸嚥炎片治療急慢性嚥喉炎療效顯著,且不良反應小,急性嚥喉炎的療效好于慢性嚥喉炎,值得臨床推廣。
목적:관찰구복염산두포타미지보이만엄서저인염편치료급성화만성인후염적림상료효화안전성。방법258례급만성인후염환자,수궤분위시험조140례(기중급성인후염76례위시험조1,만성인후염64례위시험조2)화대조조118례(기중급성인후염60례위대조조1,만성인후염58례위대조조2)。급성인후염,시험조급여염산두포타미지편+만엄서저인염편치료,대조조급여안변청매소+만엄서저인염편치료,료정위5~10 d;만성인후염급여상동치료,료정위5~21 d。대비량조료효급염산두포타미지편+만엄서저인염편치료급성화만성인후염적료효화안전성。결과급성인염유효솔시험조1위97.37%,대조조1위88.33%,차이유통계학의의(P<0.05);만성인후염유효솔시험조2위90.63%,대조조2위84.48%,차이무통계학의의(P>0.05);시험조치료급성인후염여만성인후염적료효차이무통계학의의(P>0.05),단급성인후염적료효호우만성인후염;시험조발생경도불량반응2례,대조조1례,차이무통계학의의(P>0.05)。결론염산두포타미지보이만엄서저인염편치료급만성인후염료효현저,차불량반응소,급성인후염적료효호우만성인후염,치득림상추엄。
Objective To observe clinical effect and safety of oral administration of cefetamet pivoxil hydrochloride combined with Manyanshuning Yanyan tablets in the treatment of acute and chronic pharyngolaryngitis.Methods A total of 258 patients with acute and chronic pharyngolaryngitis were randomly divided into experimental group with 140 cases (76 cases with acute pharyngolaryngitis as experimental group 1 and 64 cases with chronic pharyngolaryngitis as experimental group 2) and control group with 118 cases (60 cases with acute pharyngolaryngitis as control group 1 and 58 cases with chronic pharyngolaryngitis as control group 2). For the treatment of acute pharyngolaryngitis, the experimental group received cefetamet pivoxil hydrochloride tablets + Manyanshuning Yanyan tablets, and the control group received ampicillin + Manyanshuning Yanyan tablets. Their treatment lasted for 5~10 d. The same treatment measures were applied for treating chronic pharyngolaryngitis, while it lasted for 5~21 d. Comparisons were made on curative effects between the two groups, effect and safety of cefetamet pivoxil hydrochloride tablets + Manyanshuning Yanyan tablets in treating acute and chronic pharyngolaryngitis.Results The effective rate for acute pharyngolaryngitis was 97.37% in experimental group 1 and 88.33% in control group 1, and the difference had statistical significance (P<0.05). The effective rate for chronic pharyngolaryngitis was 90.63% in experimental group 2 and 84.48% in control group 2, and the difference had no statistical significance (P>0.05). There was no statistically significant difference of curative effect between acute and chronic pharyngolaryngitis treatment in the experimental group (P>0.05), while the curative effect for acute pharyngolaryngitis was better than that for chronic pharyngolaryngitis. There were 2 cases with adverse reactions in the experimental group and 1 case in the control group. Their difference had no statistical significance (P>0.05).Conclusion Implement of cefetamet pivoxil hydrochloride combined with Manyanshuning Yanyan tablets has precisely curative effect in the treatment of acute and chronic pharyngolaryngitis, with few adverse reactions. This method contains better curative effect for acute pharyngolaryngitis than for chronic pharyngolaryngitis, and it is worthy of clinical promotion.